TY - JOUR
T1 - SYMPHONY consortium
T2 - Orchestrating personalized treatment for patients with bleeding disorders
AU - Cnossen, Marjon H.
AU - van Moort, Iris
AU - Reitsma, Simone H.
AU - de Maat, Moniek P. M.
AU - Schutgens, Roger E. G.
AU - Urbanus, Rolf T.
AU - Lingsma, Hester F.
AU - Mathot, Ron A. A.
AU - Gouw, Samantha C.
AU - Meijer, Karina
AU - Bredenoord, Annelien L.
AU - van der Graaf, Rieke
AU - Fijnvandraat, Karin
AU - Meijer, Alexander B.
AU - van den Akker, Emile
AU - Bierings, Ruben
AU - Eikenboom, Jeroen C. J.
AU - van den Biggelaar, Maartje
AU - de Haas, Masja
AU - Voorberg, Jan
AU - Leebeek, Frank W. G.
AU - SYMPHONY consortium
AU - Cnossen, Marjon H.
AU - Reitsma, Simone H.
AU - de Haas, Masja
AU - van den Biggelaar, Maartje
AU - Leebeek, Frank W. G.
AU - Voorberg, Jan
AU - de Maat, Moniek P. M.
AU - Schutgens, Roger E. G.
AU - Urbanus, Rolf T.
AU - Lingsma, Hester F.
AU - Mathot, Ron A. A.
AU - Gouw, Samantha C.
AU - Meijer, Karina
AU - Bredenoord, Annelien L.
AU - van der Graaf, Rieke
AU - Fijnvandraat, Karin
AU - Meijer, Alexander B.
AU - van den Akker, Emile
AU - Bierings, Ruben
AU - Eikenboom, Jeroen C. J.
AU - van Moort, Iris
AU - Arisz, Ryanne A.
AU - Zivkovic, Minka
AU - Bukkems, Laura H.
AU - Cloesmeijer, Michael E.
AU - Janssen, Alexander
AU - Brands, Martijn R.
AU - Coppens, Michiel
AU - Haverman, Lotte
AU - van Hoorn, E. Shannon
AU - Goedhart, Tine M. C. H. J.
AU - Romano, Lorenzo G. R.
AU - Al Arashi, Wala
N1 - Funding Information: This research received funding from the NWO in the framework of the NWA‐ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr. M.H. Cnossen. Project manager: Dr. S.H. Reitsma. Funding Information: Symphony is an interdisciplinary research program performed by all Dutch Hemophilia Centers, academic hospitals, and research institutes, in collaboration with the patient society (NVHP), and both hematologists (NVHB) and hemostasis specialists (NVTH) as well as three pharmaceutical companies (Figures 4 and 5). Project team: Principal investigator: Dr. M.H. Cnossen. Project manager: Dr. S.H. Reitsma. Theme leaders: Prof. Dr. M. de Haas, Dr. M. van den Biggelaar (Diagnosis), Prof. Dr. F.W.G. Leebeek (Treatment), Prof. Dr. J. Voorberg (Fundamental research). WP-leaders (according to WP): WP3: Prof. dr. M.P.M. de Maat; WP4: Prof. dr. R.E.G. Schutgens, Dr. R.T. Urbanus; WP5: Dr. H.F. Lingsma; WP6: Prof. dr. R.A.A. Mathot; WP7: Dr. S.C. Gouw; WP8: Dr. H.F. Lingsma; WP9: Prof. dr. K. Meijer, Prof. dr. A.L. Bredenoord, Dr. R. van der Graaf; WP10: Prof. Dr. K. Fijnvandraat, Prof. dr. A.B. Meijer; WP11: Dr. E. van den Akker; WP12: Dr. R. Bierings, Prof.dr. H.C.J. Eikenboom. Post-doc & PhD students (according to WP): Dr. I. van Moort (WP12; post-doc); WP3: R.A. Arisz; WP4: M. Zivkovic; WP5: E.S. van Hoorn; WP6: L.H. Bukkems, M.C.H.J. Goedhart, L.G.R. Romano, W. Al Arashi, M.E. Cloesmeijer, A. Janssen; WP7: M.R. Brands; WP9: L. Baas; WP10: J. del Castillo Alferez; WP11: H. Zhang, WP12: S.N.J. Laan. Supporting and co-investigators (alphabetical order): J. Boender (Sobi-Biogen), Prof. dr. J.G. van der Bom, M.H.A. Bos (NVTH), Prof. dr. L. Burdorf. Dr. M. Coppens, Dr. M. Driessens (NVHP), Dr. K.F. Fischer, Dr. R. van der Graaf, Dr. L. Haverman, Prof. dr. J.A. Hazelzet, Drs. E.J. Huisman, N. Jansen (CSL Behring), S. de Jong (Bayer), Dr. M. Kruip, Dr. N. van Leeuwen, Dr. F. van der Meer, S. Meijer (NVHP), Prof. dr. J.K. Ploos van Amstel, Dr. S. Polinder, Dr. S.E.M. Schols, G. Wijfjes (NVHP), K. Kluft, W.L. van Heerde, G. Goedhart, Prof.dr. C. Uyl, J. Timp, A. Stekelenburg, Dr. F. Moenen, Dr. P. Ypma, Dr. L. Nieuwenhuizen, A. Plat (NVHP). Publisher Copyright: © 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: Treatment choices for individual patients with an inborn bleeding disorder are increasingly challenging due to increasing options and rising costs for society. We have initiated an integrated interdisciplinary national research program. Objectives: The SYMPHONY consortium strives to orchestrate personalized treatment in patients with an inborn bleeding disorder, by unraveling the mechanisms behind interindividual variations of bleeding phenotype. Patients: The SYMPHONY consortium will investigate patients with an inborn bleeding disorder, both diagnosed and not yet diagnosed. Results: Research questions are categorized under the themes: (1) diagnosis, (2) treatment, and (3) fundamental research, and consist of work packages addressing specific domains. Importantly, collaborations between patients and talented researchers from different areas of expertise promise to augment the impact of the SYMPHONY consortium, leading to unique interactions and intellectual property. Conclusions: SYMPHONY will perform research on all aspects of care, treatment individualization in patients with inborn bleeding disorders, as well as diagnostic innovations and results of molecular genetics and cellular model technology with regard to the hemostatic process. We believe that these research investments will lead to health-care innovations with long-term clinical and societal impact. This consortium has been made possible by a governmental, competitive grant from the Netherlands Organization for Scientific Research (NWO) within the framework of the NWA-ORC Call grant agreement NWA.1160.18.038.
AB - Background: Treatment choices for individual patients with an inborn bleeding disorder are increasingly challenging due to increasing options and rising costs for society. We have initiated an integrated interdisciplinary national research program. Objectives: The SYMPHONY consortium strives to orchestrate personalized treatment in patients with an inborn bleeding disorder, by unraveling the mechanisms behind interindividual variations of bleeding phenotype. Patients: The SYMPHONY consortium will investigate patients with an inborn bleeding disorder, both diagnosed and not yet diagnosed. Results: Research questions are categorized under the themes: (1) diagnosis, (2) treatment, and (3) fundamental research, and consist of work packages addressing specific domains. Importantly, collaborations between patients and talented researchers from different areas of expertise promise to augment the impact of the SYMPHONY consortium, leading to unique interactions and intellectual property. Conclusions: SYMPHONY will perform research on all aspects of care, treatment individualization in patients with inborn bleeding disorders, as well as diagnostic innovations and results of molecular genetics and cellular model technology with regard to the hemostatic process. We believe that these research investments will lead to health-care innovations with long-term clinical and societal impact. This consortium has been made possible by a governmental, competitive grant from the Netherlands Organization for Scientific Research (NWO) within the framework of the NWA-ORC Call grant agreement NWA.1160.18.038.
KW - bleeding disorders
KW - cellular models
KW - personalized treatment
KW - pharmacokinetics
KW - proteomics
KW - value-based health care
UR - http://www.scopus.com/inward/record.url?scp=85135862338&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jth.15778
DO - https://doi.org/10.1111/jth.15778
M3 - Article
C2 - 35652368
SN - 1538-7933
VL - 20
SP - 2001
EP - 2011
JO - Journal of thrombosis and haemostasis
JF - Journal of thrombosis and haemostasis
IS - 9
ER -